So far, no medical treatment is available for cholesteatoma (C) and the only effective therapy is complete surgical removal, but recurrence is common even after surgical treatment. While C is classically divided into two clinical phenotypes, congenital and acquired, only a few studies have focused on its potential biomarkers. This study aims to revise the literature to identify which biomarkers can define the endotype of C.
Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review / Cantone, Elena; Di Nola, Claudio; De Corso, Eugenio; Cavaliere, Michele; Grimaldi, Giusi; Fetoni, Anna Rita; Motta, Gaetano. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 12:8(2022), p. 1347. [10.3390/jpm12081347]
Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review
Cantone, Elena;Di Nola, Claudio;Cavaliere, Michele;Grimaldi, Giusi;Fetoni, Anna Rita;Motta, Gaetano
2022
Abstract
So far, no medical treatment is available for cholesteatoma (C) and the only effective therapy is complete surgical removal, but recurrence is common even after surgical treatment. While C is classically divided into two clinical phenotypes, congenital and acquired, only a few studies have focused on its potential biomarkers. This study aims to revise the literature to identify which biomarkers can define the endotype of C.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
